- Home
- HLVX
HLVX
HilleVax Inc.
as 07-26-2024 4:00pm EST
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 719.0M | IPO Year: | 2022 |
| Target Price: | $2.50 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.55 - $20.22 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of HilleVax Inc. (HLVX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kohli Aditya | HLVX | Director | May 20 '24 | Sell | $15.45 | 6,000 | $92,689.20 | 776,878 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | May 20 '24 | Sell | $14.21 | 6,000 | $85,230.00 | 770,878 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | May 20 '24 | Sell | $14.73 | 6,000 | $88,372.20 | 764,878 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | May 1 '24 | Sell | $14.03 | 175 | $2,456.00 | 789,601 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | May 1 '24 | Sell | $14.01 | 6,000 | $84,081.00 | 783,601 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | May 1 '24 | Sell | $14.15 | 723 | $10,233.49 | 782,878 | SEC Form 4 |
| Frazier Life Sciences X, L.P. | HLVX | 10% Owner | Apr 4 '24 | Buy | $14.50 | 8,850 | $128,325.00 | 8,544,187 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Apr 3 '24 | Sell | $14.93 | 6,000 | $89,581.80 | 801,776 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Apr 3 '24 | Sell | $14.71 | 6,000 | $88,245.00 | 795,776 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Apr 3 '24 | Sell | $14.44 | 6,000 | $86,640.00 | 789,776 | SEC Form 4 |
| McLoughlin Sean | HLVX | Chief Operating Officer | Mar 28 '24 | Buy | $16.98 | 1,250 | $21,225.00 | 1,250 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Mar 18 '24 | Sell | $17.66 | 6,000 | $105,936.60 | 819,776 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Mar 18 '24 | Sell | $17.42 | 6,000 | $104,491.80 | 813,776 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Mar 18 '24 | Sell | $164,221.00 | 6,000 | $985,326,000.00 | 807,776 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Mar 6 '24 | Sell | $18.95 | 6,000 | $113,700.60 | 837,776 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Mar 6 '24 | Sell | $18.37 | 6,000 | $110,212.80 | 831,776 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Mar 6 '24 | Sell | $18.66 | 6,000 | $111,958.80 | 825,776 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Feb 20 '24 | Sell | $14.88 | 6,000 | $89,271.60 | 855,776 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Feb 20 '24 | Sell | $14.92 | 6,000 | $89,494.80 | 849,776 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Feb 20 '24 | Sell | $15.05 | 6,000 | $90,312.00 | 843,776 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Feb 12 '24 | Sell | $15.32 | 6,000 | $91,920.60 | 861,776 | SEC Form 4 |
| HERSHBERG ROBERT | HLVX | See Remarks | Feb 8 '24 | Sell | $14.93 | 11,597 | $173,160.61 | 953,831 | SEC Form 4 |
| Kohli Aditya | HLVX | Director | Feb 8 '24 | Sell | $14.93 | 8,866 | $132,382.68 | 812,878 | SEC Form 4 |
| Maltbie Shane | HLVX | Chief Financial Officer | Feb 8 '24 | Sell | $14.93 | 3,576 | $53,395.04 | 40,656 | SEC Form 4 |
| Borkowski Astrid | HLVX | Chief Medical Officer | Feb 8 '24 | Sell | $14.93 | 3,933 | $58,725.59 | 161,260 | SEC Form 4 |
Latest HilleVax Inc. News
HLVX Breaking Stock News: Dive into HLVX Ticker-Specific Updates for Smart Investing
Zacks
15 days ago
Down -88.84% in 4 Weeks, Here's Why HilleVax (HLVX) Looks Ripe for a Turnaround
Zacks
15 days ago
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
Zacks
17 days ago
HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails
MT Newswires
18 days ago
US Equities Markets End Mixed as Investors Await Inflation Data
MT Newswires
18 days ago
Sector Update: Health Care Stocks Softer Late Afternoon
MT Newswires
18 days ago
Sector Update: Health Care
MT Newswires
18 days ago
Top Midday Decliners
MT Newswires
18 days ago
HilleVax's Acute Gastroenteritis Vaccines Fails Main Goal in Phase 2 Study; Shares Plunge Premarket
Compare HLVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HLVX HilleVax Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.